Well, since that works BOTH WAYS this also makes the case that the absence of a partnership has no meaning of what so ever as to the value of bavituximab or the companies ability to make a deal.
Because if we don't know in ONE direction - because we don't know - then we also don't know in the OTHER direction - because we don't know.
So that means EVERYTHING is OK and BIG TIME all right until we know, because from the COURT FILING we KNOW at least that with AbbVie there was something on the table management did not see as breadcrumbs and that they apparently were able to make a deal (crossed by the dose switching incident which only people of bad will will hold against them not wanting to accept "force majeure").
Market Data 
Markets 
AI
